Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors

This study sought to investigate the clinical outcome and the role of postoperative radiotherapy for patients with salivary duct carcinoma (SDC) who had undergone surgery and postoperative radiotherapy. We performed a retrospective analysis of 25 SDC patients treated between 1998 and 2011 with surgery and postoperative radiotherapy. The median prescribed dose was 60 Gy (range, 49.5–61.4 Gy). The clinical target volume (CTV) was defined as the tumor bed in four patients, the tumor bed and ipsilateral neck in 14 patients, and the tumor bed and bilateral neck in six patients. Local control (LC), disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and prognostic variables were analyzed with the log-rank test. The 5-year LC, DFS and OS were 67%, 45% and 47%, respectively. Disease recurrence was found in 12 patients: seven as local, four as regional and eight as distant failure. Perineural and lymphovascular invasion was a significant prognostic factor for LC (P = 0.03). Local failure was common, and the presence of local recurrence significantly affected the OS (P < 0.05). We conclude that surgery and postoperative radiotherapy is expected to decrease the risk of local failure and contribute to good prognoses for patients with SDC. It might be advisable to have the CTV include the cranial nerves involved and the corresponding parts of the skull base in cases of pathologically positive perineural invasion.

[1]  Hongyu Yang,et al.  Salivary duct carcinoma of the parotid gland: A case report and review of the literature , 2014, Oncology letters.

[2]  S. Nam,et al.  Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands. , 2012, The British journal of radiology.

[3]  S. Kim,et al.  Salivary duct carcinomas: clinical and CT and MR imaging features in 20 patients , 2012, Neuroradiology.

[4]  A. Mäkitie,et al.  Management and outcome of salivary duct carcinoma in major salivary glands , 2012, European Archives of Oto-Rhino-Laryngology.

[5]  S. Piao,et al.  Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.

[6]  P. Slootweg,et al.  Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. De Riu,et al.  Management of midcheek masses and tumors of the accessory parotid gland. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[8]  R. Weber,et al.  Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance , 2010, Clinical Cancer Research.

[9]  Y. Ko,et al.  Expression of mitotic checkpoint proteins BUB1B and MAD2L1 in salivary duct carcinomas. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[10]  S. Takashima,et al.  Salivary duct carcinoma of the parotid gland: clinical and MR features in six patients. , 2009, The British journal of radiology.

[11]  J. Roh,et al.  Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma , 2008, Journal of surgical oncology.

[12]  J. Sercarz,et al.  Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy , 2007, Head & neck.

[13]  R. Dodd,et al.  Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. , 2006, Oral oncology.

[14]  T. Löning,et al.  Clinical and immunohistologic typing of salivary duct carcinoma , 2005, Cancer.

[15]  R. Valeri,et al.  Salivary Duct Carcinoma of the Parotid Gland , 2005, Acta Cytologica.

[16]  S. Pambuccian,et al.  Salivary Duct Carcinoma , 1998, Acta Cytologica.

[17]  C. Grandi,et al.  Salivary duct carcinoma: Clinical characteristics and treatment strategies , 1997, Head & neck.

[18]  A. Garden,et al.  The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. , 1995, International journal of radiation oncology, biology, physics.

[19]  C. Colmenero Ruiz,et al.  Salivary duct carcinoma: a report of nine cases. , 1993, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[20]  W. Hong,et al.  Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.